Transparency in clinical trials is continually changing, and to stay on top of the news, TrialAssure brings a weekly round-up of some of the key stories surrounding disclosures in clinical trials. This week’s stories are as follows:

Gottlieb successor promises to maintain current FDA priorities – CenterWatch

Acting FDA Commissioner Ned Sharpless pledges to maintain current FDA priorities as defined by his predecessor, Scott Gottlieb. As an oncologist by training, Sharpless considers himself a champion of real-world data and is excited by its implications.

CenterWatch has the story here

Why is uploading clinical results onto trial registries so important? – TranspariMED

Data posted onto clinical trial registries are more reliable than those published in journal articles, according to reporter Till Bruckner. Some university researchers, however, still believe that clinical data exclusively published in a peer-reviewed journal is sufficient.

Read the full article by Till Bruckner

TrialAssure amplifies clinical trial transparency functionality with the release of REGISTRY 2.5  Applied Clinical Trials

TrialAssure announced the launch of REGISTRY 2.5, the latest iteration of TrialAssure’s premiere clinical trial registration and disclosure reporting application with a configurable workflow engine that allows clients to augment regulatory intelligence for global registries. TrialAssure REGISTRY 2.5 is a smarter application that auto-calculates workflow steps based on project progress.

Read the press release via Applied Clinical Trials

Data protection in the pharma sector: a many-headed hydra –The Pharma Letter

In an Expert View piece for The Pharma Letter, Oliver Kidd, senior associate at Stevens & Bolton, provides an overview of data protection in the pharma industry.

Read the Expert View piece here